Zambia’s National Health Insurance Making Progress Towards Strategic Purchasing of Quality Care
Recent Posts
Key Decisions on Health Technology Assessment at ACP124: Implications for Rare Disease Therapies
Health technology assessment (HTA) plays a crucial role in determining whether new therapies are reimbursed within healthcare systems. At the July 18, 2025 meeting of the Adviescommissie Pakket (ACP), two high-profile orphan drugs—omaveloxolone (Skyclarys®) for Friedreich’s ataxia and exagamgloge...
Unlocking Self-Care South Africa: Strategies and Challenges in Healthcare Reform
The recent interview with Nicola Brink, CEO of the Self-Care Association of South Africa, published by Executive Forecast, highlights both the systemic challenges and transformative opportunities within the country’s self-care South Africa sector. The article details persistent regulatory delays—...
Rare Medications Coverage in the Netherlands: Price Reductions Required
Zorginstituut Nederland has announced that two rare disease medications, exagamglogene autotemcel (Casgevy®) and omaveloxolon (Skyclarys®), will only be covered by Dutch basic health insurance if their prices drop significantly. For omaveloxolon, treating Friedreich's ataxia, an 84% price cut is ...